The impact of a successful treatment of hepatitis C virus by Direct Acting Antiviral Drugs (DAAS) on Glycemic Control of Diabetic HCV Infected Patients

Abstract

Approximately, 130–150 million people are infected with HCV; each year, besides an estimated 399 000 people die from complications of HCV including cirrhosis, malignant neoplastic disease (hepatocellular carcinoma) and liver failure. Unluckily, many people with HCV only know about their infection when they experience symptoms of cirrhosis or liver cancer. The association between hepatitis C virus (HCV) infection and diabetes has been widely postulated. Prospective studies have demonstrated a higher risk of developing type 2 diabetes mellitus (T2DM) and insulin resistance in the HCV population. Therefore, it is presumed that effective HCV management would result in improved glycemic control in diabetic patients. Recently, a growing body of evidence has shown a promising role of effective HCV eradication on glycemic control of diabetic patients; previous reports showed that the change in HbA1c was greater in those who achieved SVR with DAAs than in those who sustained treatment failure. Aim of this study was to evaluate effect of treatment of hepatitis C virus by Direct Acting Antiviral Drugs (DAAS) on Glycemic Control of Diabetic HCV Infected Patients This study was conducted in viral hepatitis treatment center at Aswan Fever.